Cardio & Vascular was Integer Holdings’s largest product and service line in fiscal 2025, bringing in $1.11B of $1.85B (60%).
| Product and Service | FY 2010 | FY 2011 | FY 2012 | FY 2014 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|
| Cardio & Vascular | $699.40M | $836.34M | $949.58M | $1.11B | ||||
| Cardiac Rhythm Management Neuromodulation | $534.37M | $612.89M | $660.61M | $668.80M | ||||
| Cardiac/Neuromodulation | — | — | — | — | ||||
| Cardiac Neuromodulation | — | — | — | — | ||||
| Salesrevenuenet | — | — | — | — | ||||
| Advanced Surgical, Orthopaedics, & Portable Medical | — | — | — | — | ||||
| Orthopaedic | — | — | — | — | ||||
| Other Markets | $97.51M | $106.42M | $106.41M | $77.75M | ||||
| Electrochem | — | — | — | — | ||||
| Energy | — | — | — | — | ||||
| Vascular | — | — | — | — | ||||
| Portable Medical | — | — | — | — | ||||
| Other Products & Services | — | — | — | — | ||||
| Total | $1.33B | $1.56B | $1.72B | $1.85B |
Integer Holdings brought in $1.85B from its three product and service lines in fiscal 2025, the year ended December 31, 2025. That was up 8.0% from $1.72B in fiscal 2024. Cardio & Vascular was the largest at $1.11B (59.7%), ahead of Cardiac Rhythm Management Neuromodulation at $668.80M (36.1%) and Other Markets at $77.75M (4.2%).
Compared with fiscal 2024, Cardio & Vascular grew fastest, up 16.6% to $1.11B, while Other Markets fell the most, down 26.9% to $77.75M. From fiscal 2022 to 2025, combined revenue from these lines grew from $1.33B to $1.85B, a compound annual growth rate of 11.7%. Cardio & Vascular's share of the total rose from 52.5% to 59.7%.
U.S was Integer Holdings’s largest region in fiscal 2025, bringing in $979.81M of $1.85B (53%).
| Geography | FY 2010 | FY 2011 | FY 2012 | FY 2014 | FY 2015 | FY 2016 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| U.S | $732.60M | $872.93M | $938.68M | $979.81M | ||||||||||||
| United States | — | — | — | — | ||||||||||||
| Salesrevenuenet | — | — | — | — | ||||||||||||
| Rest Of World | $408.46M | $383.73M | $431.76M | $469.89M | ||||||||||||
| Puerto Rico | $114.08M | $121.49M | $137.06M | $131.26M | ||||||||||||
| Costa Rica | $76.14M | $108.42M | $124.69M | $173.52M | ||||||||||||
| Ireland | — | $69.09M | $84.41M | $99.16M | ||||||||||||
| Belgium | — | — | — | — | ||||||||||||
| United Kingdom Ireland | — | — | — | — | ||||||||||||
| Total | $1.33B | $1.56B | $1.72B | $1.85B |
Integer Holdings brought in $1.85B from its five regions in fiscal 2025, the year ended December 31, 2025. That was up 8.0% from $1.72B in fiscal 2024. U.S was the largest at $979.81M (52.9%), ahead of Rest Of World at $469.89M (25.3%) and Costa Rica at $173.52M (9.4%). The other two regions brought in $230.42M combined.
Compared with fiscal 2024, Costa Rica grew fastest, up 39.2% to $173.52M, while Puerto Rico fell the most, down 4.2% to $131.26M.
Integer Holdings began breaking out Ireland in fiscal 2023, when it brought in $69.09M.
Integer Holdings (ITGR) reports its revenue by product and service and by geography. In fiscal 2025, Cardio & Vascular was its largest product and service line, bringing in $1.11B (59.7% of the total), followed by Cardiac Rhythm Management Neuromodulation at $668.80M (36.1%).
Cardio & Vascular was Integer Holdings' largest product and service line in fiscal 2025, bringing in $1.11B, or 59.7% of the $1.85B total across its three product and service lines.
U.S was Integer Holdings' largest region in fiscal 2025, bringing in $979.81M, or 52.9% of the $1.85B total across its five regions.
Among Integer Holdings' product and service lines that make up at least 2% of revenue, Cardio & Vascular grew fastest in fiscal 2025, up 16.6% from $949.58M to $1.11B.
Every figure comes from Integer Holdings' annual financial filings, as reported. Each line keeps the name Integer Holdings gives it, and years follow its fiscal calendar.
Integer Holdings' revenue by product and service goes back to fiscal 2010, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.